NASDAQ: CSBRChampions Oncology Inc Stock
$5.03-0.04 (-0.79%)
Updated Apr 24, 2024
CSBR Price
$5.03
Fair Value Price
$1.78
Market Cap
$68.38M
52 Week Low
$4.17
52 Week High
$7.32
P/E
-6.99x
P/B
-33.22x
P/S
1.6x
PEG
N/A
Dividend Yield
N/A
Revenue
$49.22M
Earnings
-$9.73M
Gross Margin
40.1%
Operating Margin
-19.62%
Profit Margin
-19.8%
Debt to Equity
-14.02
Operating Cash Flow
-$5M
Beta
0.8
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CSBR Overview
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CSBR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CSBR ($5.03) is overvalued by 183.24% relative to our estimate of its Fair Value price of $1.78 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CSBR ($5.03) is not significantly undervalued (183.24%) relative to our estimate of its Fair Value price of $1.78 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CSBR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CSBR due diligence checks available for Premium users.
Be the first to know about important CSBR news, forecast changes, insider trades & much more!
CSBR News
Valuation
CSBR fair value
Fair Value of CSBR stock based on Discounted Cash Flow (DCF)
Price
$5.03
Fair Value
$1.78
Overvalued by
183.24%
CSBR ($5.03) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CSBR ($5.03) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CSBR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CSBR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.99x
Industry
15.69x
Market
41.27x
CSBR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-33.22x
Industry
5.86x
CSBR's financial health
Profit margin
Revenue
$12.0M
Net Income
-$2.5M
Profit Margin
-21.1%
CSBR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CSBR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$26.8M
Liabilities
$28.8M
Debt to equity
-14.02
CSBR's short-term liabilities ($21.97M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CSBR's short-term assets ($13.20M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CSBR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CSBR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$919.0k
Investing
-$126.0k
Financing
$0.0
CSBR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CSBR vs Biotech Stocks
Champions Oncology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.